Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma

Inclusion criteria

• Patients age: ≥ 18 years
• Patients should have a history of Barrett's associated esophageal dysplasia (either low or high-grade) confirmed on histology
• Willingness to undergo both WATS3D and random forceps biopsies while undergoing conventional EGD with sedation
• Ability to provide written, informed consent (approved by IRB) and understand the responsibilities of trial participation
• Only patients who no visible mucosal abnormalities at the time that they undergo both random forceps biopsies and WATS3D testing of the esophagus will be included in this study

Exclusion criteria

• Coagulopathy with INR > 2.0, thrombocytopenia with platelet counts < 50,000
• The subject is pregnant or planning a pregnancy during the study period
• History of esophageal or gastric surgery other than Endoscopic Mucosal Resection (EMR)
• Patients who have undergone endoscopic ablative therapies
• Subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines
• Study patients with inadequate WATS3D specimens will not undergo a repeat brush biopsy test and will be excluded from the study
• BE length < 1 cm or > 10 cm
• Patients within six weeks of receiving targeted forceps biopsies and/or EMR
• Patients with visible mucosal abnormality at the time of the WATS3D and random biopsy testing
• Patients with visible lesions that are either submucosal or covered with a clinically intact epithelium